Navigation Links
Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment
Date:11/3/2011

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the 56-week EQUIP study were published in Obesity, the peer-reviewed journal of The Obesity Society. The EQUIP study evaluated the efficacy and safety of the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 kg/m2) patients across 91 sites in the US. In addition to average weight loss of 14.4% of initial body weight among those who completed the study at the top dose of Qnexa, severely obese patients had improvements in blood pressure, glucose, triglycerides and cholesterol. The results with Qnexa suggest the potential to effectively treat severely obese patients without surgery.

"Obesity is a serious medical condition that threatens the public health and reduces the quality and length of lives. Currently available treatments are limited and options are needed," said lead investigator Dr. David Allison, director of the Nutrition Obesity Research Center, University of Alabama at Birmingham. "In this population of severely obese patients, those taking Qnexa experienced significant weight loss and reduction in risk factors for many chronic diseases. The results refute a common notion that nonsurgical treatments are not effective for extremely obese persons. The findings are especially relevant to the 14% of the US adult population classified as extremely obese."

Patients in the study had a baseline body mass index of >/= 35 kg/m2, and an average initial weight of 256 pounds. Treatment was well tolerated, with no evidence of serious adverse events induced by treatment.

Specific weight loss results for all patients through 56 weeks as published in Obesity are as follows:

  • Least-squares (LS) mean weight loss for Qnexa patients who completed the EQUIP study was 14.4% and 6.7% with top-dose Qnexa
    '/>"/>

  • SOURCE VIVUS, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Multiple Presentations Featuring QNEXA® Data to be Presented at the European Congress on Obesity
    2. QNEXA® Phase 3 Data in The Lancet Show Significant Weight Loss and Broad Improvements in Co-Morbidities
    3. Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits
    4. Long-Term Data on QNEXA® to be Presented at The American College of Cardiology Annual Meeting
    5. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
    6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
    7. New Long-Term Data on QNEXA® Show Significant and Sustained Weight Loss of Greater Than 10% Over Two Years
    8. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
    9. Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
    10. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
    11. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has ... (London, UK - November 16-18, 2015)" conference to their offering. ... including Columbia, Peru , Brazil ... Uruguay , Paraguay , ... , Chile This seminar can ...
    (Date:9/2/2015)... , Sept. 2, 2015  Seeger Weiss LLP is ... trial will commence October 13, 2015. ... 510K fast-track approval program, Zimmer NexGen knee implant surpassed ... requires that companies provide evidence that the product is ... order to gain permissions. In 2001, ...
    (Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cnq7tc/medical_device ) has ... Studies: Clinical Evidence (London, UK - November 10-11, ... This course has been designed specifically for ... required for medical devices and in-vitro diagnostic products. ... and the emphasis on high quality, appropriate clinical ...
    Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2
    ... Quest Diagnostics Incorporated (NYSE: DGX ), the ... today that it will report third quarter 2010 results on ... its quarterly conference call with investors to discuss the results ... The public may access the conference call through a live ...
    ... Calif., Sept. 28 Molecular Devices, Inc., ... discovery & development, life science research, and ... taking orders for its new IonWorks Barracuda™ ... (Logo:   http://photos.prnewswire.com/prnh/20100406/SF82092LOGO ) (Logo: ...
    Cached Medicine Technology:Quest Diagnostics to Release Third Quarter 2010 Financial Results 2New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays 2
    (Date:9/2/2015)... ... ... Telehealth represents a growing trend among Blue Cross and Blue Shield plans, with ... 12 Blues plan clients. The September 2015 issue of The AIS Report ... executives at Capital Blue Cross, whose telehealth services will launch next year. Published independently ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the September ... pharmaceutical researchers to participate in interactive programs in which ERT scientists and ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Density ... or final products. Automating sample handling makes density measurements more efficient and error-free. ... step of the automated workflow and the advantages compared to manual sample handling. ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Alameda County Community Food Bank ... Month” during the entire month of September. In the spirit of the ... efforts this September to an awareness campaign educating legislators and the public on ...
    (Date:9/2/2015)... Appleton, WI (PRWEB) , ... September 02, 2015 ... ... Midwest, Cypress Benefit Administrators is taking action after seeing a significant ... The TPA’s Argus Claim Review division has found many cases of OON ASCs ...
    Breaking Medicine News(10 mins):Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3
    ... of one of the nation,s largest Medicare chronic condition special ... care for seniors with chronic illness, today announced the appointment ... effective August 1, 2009. , , Prior to ... CEO of United HealthCare,s Evercare healthplans, the business unit that ...
    ... ... readership with a forum to share their insights and views with their constituents, Jackson & ... in the Jackson & Coker Industry Report , ... Atlanta, GA (Vocus) July 6, 2009 -- To further provide it’s executive ...
    ... General Dynamics Information Technology, a business unit of General Dynamics ... million dollar, three-year contract to support the U.S. Army Medical ... , General Dynamics will support the Army MEDCOM Lean Six ... services to internal organizations for MEDCOM,s Director of Strategy and ...
    ... is increasingly becoming a networked process. The big genome studies ... efforts of gold standard centers around the world. Only in ... as those obtained by the GenoMEL project, which is funded ... risk factors for melanoma. The objective is to translate this ...
    ... Villanova University , the leader in ... education offerings with the world,s only 100% online Advanced ... enabling those with Black Belt training to ... this program examines business processes from a holistic perspective, ...
    ... gender bias, however , MONDAY, July 6 (HealthDay News) -- ... be active if their parents like team sports, U.S. researchers ... and fifth-grade students at 12 schools in Houston to reach ... of parents who valued high-intensity team sports watched less TV, ...
    Cached Medicine News:Health News:Dr. John Mach Appointed Chief Medical Officer at XLHealth 2Health News:Jackson & Coker to Spotlight Health Care Executive Insights 2Health News:Jackson & Coker to Spotlight Health Care Executive Insights 3Health News:General Dynamics Awarded $9 Million Contract for U.S. Army Medical Command Lean Six Sigma Support 2Health News:The GenoMEL project identifies a new region of the genome associated with the risk of melanoma 2Health News:New Villanova University Online Course Enables Black Belts to Attain Lean Master Black Belt Certification 2Health News:New Villanova University Online Course Enables Black Belts to Attain Lean Master Black Belt Certification 3Health News:Kids of Parents Who Value Exercise Are More Active 2
    ... technology is here! LTF™ (Layered Thin Film) ... test platform that is easy to read, ... as a credit card. What is Infectious ... reason women visit their physician. Vaginal discharge ...
    ... test! QuickScreen multi-panel dip cards offer minimal ... choice of any conceivable combination of 9 ... for your drug testing program. Just dip ... built-in timer tells you when to read ...
    ... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
    Accu-Stat Home Drug Test for Marijuana (THC), Cocaine (COC), Amphetamine (AMP), Methamphetamine (mAMP), Opiates (OPI), and Phencyclidine (PCP)....
    Medicine Products: